Regeneron Pharmaceuticals And Sanofi Announce FDA Approval For Dupixent In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Natera Analyst Ratings
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
US stocks closed: Technology breaks through to lift the index, Nasdaq and S&P jointly achieve four consecutive gains.
① After four consecutive days of gains, the S&P 500 index is still 1.3% away from its historical high. ② Warren Buffett's deputy sold more than half of Berkshire Hathaway's positions, causing the stock price to fall for the seventh consecutive day. ③ AirPods Pro transforms into an OTC hearing aid, with FDA approval for Apple's hearing assistance software. ④ Gilead's HIV prevention drug delivers positive results once again.
Gilead Sciences Goes Ex-dividend Tomorrow
Cracking The Code: Understanding Analyst Reviews For Exact Sciences
What the Options Market Tells Us About Gilead Sciences
Gilead Posts Second Late-stage Win for Twice-yearly HIV Therapy
Gilead Shares Are Trading Higher After the Company Announced Interim Results From a Phase 3 Trial Showing That Twice-yearly Lenacapavir Reduced HIV Infections by 96%.
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Exact Sciences Analyst Ratings
Sanofi Reports Positive Phase 3 Results for Dupixent for CSU
UnitedHealth Follows Competitors, Replaces Humira With Lower-Cost Biosimilars
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
Exact Sciences Spikes Ahead of Data for Blood-based Cancer Test
What the Options Market Tells Us About AbbVie
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Viking Therapeutics Unusual Options Activity For September 11